NIH's Entire High-Risk Portfolio Comes Due in Eight Days: Transformative September 3, Pioneer September 9, Early Independence September 10

The NIH Common Fund's High-Risk, High-Reward program exists because the standard R01 study section is structurally bad at funding ideas with no preliminary data. Four mechanisms, one review culture, and an explicit instruction to reviewers to weigh significance and innovation over feasibility evidence.

For FY2027, all four opened within days of each other in late June, and three of them close within eight days of each other starting Thursday.

Roughly $44.7 million and about 54 awards for the whole high-risk portfolio of the largest biomedical funder on earth. Every deadline is 5:00 PM local time — the applicant organization's local time, not Eastern — and the earliest start date across all four is July 2027.

Early Independence skipped a year, and the eligibility window shows it

The most consequential detail in the FY2027 slate is not in any of the four RFAs. It is in what happened to the third one.

The FY2026 Early Independence Award funding opportunity never went forward. NIH attributed the cancellation to administrative changes in funding-opportunity processing and delays in approvals. Existing DP5 awardees continued; the competition simply did not happen.

RFA-RM-27-004 absorbs that gap in its eligibility clause. Applicants must have completed their terminal doctoral degree or clinical training between May 1, 2025 and September 30, 2027 — a 29-month window where the program normally runs a rolling 12-to-18-month band. Two cohorts are being funneled into one competition for approximately 10 awards.

If you are a 2025 or early-2026 PhD who assumed the DP5 was gone, it is not, and this is the cycle. If you are a 2027 graduate, you are eligible now against a field that includes people two years further along. The program has always been built for the rare postdoc-skipper, but the applicant pool this cycle is unusually deep, and that is a function of a canceled competition rather than a surge of interest.

The DP5's structural requirements are unchanged and remain the hardest part of the application:

• Single PD/PI only. No multi-PI.
• The applicant must currently be non-independent — research requires mentor approval and is primarily supported through someone else's funding.
• Maximum 12 months of postdoctoral experience if you hold an earlier doctoral degree.
• 80 percent effort in years 1 and 2.
• A guaranteed independent position secured before the award start date.
• $350,000/year in direct costs, plus indirect, for up to five years.

That last requirement is the one that ends most DP5 applications. An institution must commit to treating a person with no independent funding history as faculty-equivalent, in writing, before NIH has committed a dollar. The applications that succeed are the ones where the institutional letter reads like a signed contract rather than an expression of enthusiasm. Start that conversation today if you have not — twelve days is thin for a commitment that usually requires a dean.

Pioneer and Transformative: same money, opposite bets

Pioneer (RFA-RM-27-001) and Transformative (RFA-RM-27-003) each carry approximately $8 million and approximately 7 awards in FY2027. They are the same size and they are looking for different things.

Pioneer funds a person. $700,000 per year in direct costs, a project period of September 1, 2027 through August 31, 2032, and a hard requirement that the PD/PI commit more than 6 person-months — 51 percent — of research effort in each of the first three years. Applications with multiple PD/PIs "will not be accepted." An individual may submit only one application as PD/PI; an institution may submit multiple scientifically distinct ones. The award is aimed at scientists with an outstanding record of creativity who are changing direction, and the 51 percent effort floor is the mechanism that makes it real — you cannot run a Pioneer as one of six projects.

Transformative funds an idea, and it is the only HRHR mechanism that accepts teams. RFA-RM-27-003 is explicitly "for Individual and Group Science." Application budgets are not capped — they "must be commensurate with the scope of the proposed research" — over a maximum five-year period. With about $8 million for about 7 awards, the implied average lands near $1.1 million total per award, so the absence of a cap is a scoping instrument rather than an invitation. It lets a genuinely expensive idea ask for what it costs, at the price of being visibly the reason fewer awards get made.

Two shared features are worth internalizing before you write.

Preliminary data are not required, and substantial preliminary data are discouraged. This is not boilerplate. Reviewers on HRHR panels are instructed to weigh significance and innovation, and a Transformative application padded with pilot results reads as a project that belongs in a study section. The three scored criteria are Importance of the Research, Rigor and Feasibility, and Expertise and Resources — in that order.

Foreign organizations and foreign subawards are prohibited across the slate. Unfunded collaborations and foreign consultants remain permissible. If your idea requires a foreign partner to hold a budget line, restructure it or submit elsewhere.

One procedural line in RFA-RM-27-003 deserves a flag: reconsideration requests are not accepted for applications submitted under this NOFO. If your application is administratively withdrawn — wrong form, missing attachment, a page-limit violation — there is no appeal. The NOFO also carries an expiration date of September 4, 2026, one day after the due date. There is no grace period built into that structure.

The denominator is getting worse, and it is not a rumor

None of these numbers should be read in isolation from the budget environment they land in.

The FY2027 President's Budget Request proposes $41.2 billion for NIH — a $6 billion, roughly 13 percent cut from the enacted FY2026 level of $47.2 billion. Under that request, the number of competing awards would fall by 47 percent, and the overall success rate would drop to 7.8 percent, down from 14.9 percent in FY2026.

A request is not an appropriation, and Congress has repeatedly declined to enact proposed NIH cuts. But applicants are making submission decisions now against a pipeline that is already tightening — reporting through 2026 has documented slowing award flow and mounting confusion about what gets funded and when. The Common Fund's HRHR line is a small, protected carve-out, which historically has made it more stable than the institute-by-institute research portfolio in bad years, not less. That is an argument for submitting, not against it.

It also interacts with the other structural change NIH has pushed this year. The proposed cap on simultaneous research project grants — NOT-OD-26-086, which drew more than 3,300 comments — would redistribute funding away from the most heavily funded investigators. A Pioneer award, with its 51 percent effort commitment, consumes an unusual amount of a PI's capacity for a single grant. Anyone modeling their portfolio against a possible RPG cap should think about what a Pioneer does to their remaining room.

What to do between now and September 10

If you are writing Transformative (Thursday): stop adding preliminary data. Spend the remaining time on the first scored criterion — Importance of the Research — and on making the group structure legible if you have one. Confirm the exact 5:00 PM deadline in your organization's local time zone, and confirm your eRA Commons registration is current, because the submission is not complete until it clears Commons, not Grants.gov.

If you are writing Pioneer (September 9): verify that your effort commitment across all current and pending support leaves room for 51 percent in years 1 through 3. This is the most common reason a strong Pioneer application becomes non-viable at the institutional signoff stage, and it surfaces late. Confirm you are the sole PD/PI on the record — a multi-PI submission will not be accepted, not merely scored down.

If you are writing Early Independence (September 10): the science is the smaller problem. Get the institutional commitment letter drafted and routed today. It must speak to a guaranteed independent position, space, and the 80 percent effort protection, and it must be signed by someone who can actually bind the institution.

If you missed New Innovator on August 17: these RFAs are reissues on an annual cadence — RFA-RM-27-001 reissues RFA-RM-25-001, RFA-RM-27-003 reissues RFA-RM-25-003, RFA-RM-27-004 reissues RFA-RM-24-005. Expect the FY2028 slate to post in late June 2027 with the same structure. The New Innovator's $475,000 per year for Early Stage Investigators is the largest of the four cohorts at about 30 awards, and an ESI who is still within the eligibility window has a materially better ratio there than in any other HRHR lane.

Fifty-four awards for the entire high-risk apparatus of American biomedical science is a small number. It was a small number in good budget years too. What has changed is that the mechanisms around it are shrinking faster, which makes the eight days ahead worth more than the calendar suggests.